Hyperion DeFi Reports Record Q1 Net Income, Raises FY26 Guidance, and Boosts Cash Reserves
HYPD has more than doubled off its 52-week low of $1.08.
Summary
Hyperion DeFi reported record Q1 2026 net income and Adjusted EBITDA, significantly raised its full-year guidance, and substantially increased its cash reserves, signaling a strong financial turnaround.
Key Events · Earnings and Guidance · HYPD
-
Record Q1 2026 Financial Results
The company reported a net income of $8.8 million and Adjusted EBITDA of $19.5 million for Q1 2026, a significant turnaround from the previous quarter's net loss of ($39.8 million) and Adjusted EBITDA of ($38.9 million).
-
Full-Year 2026 Guidance Raised
Hyperion DeFi increased its full-year 2026 Adjusted Gross Profit guidance from a range of $4M-$6M to $5M-$7M, reflecting improved operational outlook.
-
Substantial Increase in Cash Reserves
Cash, cash equivalents, and USDH grew to approximately $16.0 million as of May 11, 2026, up from $9.1 million at the end of Q1 2026 and $6.5 million at the end of Q4 2025.
-
Underwriter Option Exercise
The company issued 132,249 shares of common stock to Chardan Capital Markets, LLC, generating approximately $0.4 million in net proceeds from the exercise of a 30-day over-allotment option related to a prior offering.
Analysis · HYPD · Life Sciences
Hyperion DeFi announced a significant financial turnaround for Q1 2026, reporting record net income of $8.8 million and Adjusted EBITDA of $19.5 million. This marks a dramatic improvement from the previous quarter's substantial losses and follows recent disclosures of digital asset impairment and material weaknesses in internal controls. The company also raised its full-year 2026 Adjusted Gross Profit guidance from $4M-$6M to $5M-$7M, indicating increased confidence in its DeFi operating segments. Furthermore, cash, cash equivalents, and USDH reserves grew to $16.0 million as of May 11, 2026, significantly strengthening its liquidity. The filing also noted the exercise of an underwriter's option, resulting in the issuance of 132,249 shares and approximately $0.4 million in net proceeds, a minor dilutive event compared to the strong financial performance.
At the time of this filing, HYPD was trading at $3.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $1.08 to $17.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.